Long-term outcomes of total elbow arthroplasty for distal humeral fracture: results from a prior randomized clinical trial.


Journal

Journal of shoulder and elbow surgery
ISSN: 1532-6500
Titre abrégé: J Shoulder Elbow Surg
Pays: United States
ID NLM: 9206499

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 06 11 2018
revised: 04 06 2019
accepted: 07 06 2019
pubmed: 26 8 2019
medline: 18 1 2020
entrez: 26 8 2019
Statut: ppublish

Résumé

Total elbow arthroplasty (TEA) is a reliable treatment for elderly patients with comminuted intra-articular distal humeral fractures. However, the longevity and long-term complications associated with this procedure are unknown. The objectives of this study were to examine long-term outcomes and implant survival in elderly patients undergoing TEA for fracture. Patients from a previously published randomized controlled trial of 42 patients in which TEA was compared with open reduction-internal fixation (ORIF) were followed up long term. Patients were aged 65 years or older with comminuted intra-articular distal humeral fractures. Outcomes included patient-reported grading of function and pain, revision surgical procedures, and implant survival. Data were obtained for 40 patients, 15 treated with ORIF and 25 treated with TEA, with a mean follow-up period of 12.5 years for surviving patients and 7.7 years for deceased patients. The reoperation rate was 3 of 25 in the TEA group and 4 of 15 in the ORIF group (P = .39). Of the 25 patients with TEAs, only 1 required (early) revision arthroplasty; 7 were living with their original arthroplasty, and 15 died with a well-functioning implant in situ. Three were lost to follow-up. TEA is an effective and reliable procedure for the treatment of comminuted distal humeral fractures in the elderly patient. Our study reveals reliable implant long-term survival, with no patient requiring a late revision. For the majority of these patients, a well-performed TEA will give them a well-functioning elbow for life and will be the last elbow procedure required.

Sections du résumé

BACKGROUND BACKGROUND
Total elbow arthroplasty (TEA) is a reliable treatment for elderly patients with comminuted intra-articular distal humeral fractures. However, the longevity and long-term complications associated with this procedure are unknown. The objectives of this study were to examine long-term outcomes and implant survival in elderly patients undergoing TEA for fracture.
METHODS METHODS
Patients from a previously published randomized controlled trial of 42 patients in which TEA was compared with open reduction-internal fixation (ORIF) were followed up long term. Patients were aged 65 years or older with comminuted intra-articular distal humeral fractures. Outcomes included patient-reported grading of function and pain, revision surgical procedures, and implant survival.
RESULTS RESULTS
Data were obtained for 40 patients, 15 treated with ORIF and 25 treated with TEA, with a mean follow-up period of 12.5 years for surviving patients and 7.7 years for deceased patients. The reoperation rate was 3 of 25 in the TEA group and 4 of 15 in the ORIF group (P = .39). Of the 25 patients with TEAs, only 1 required (early) revision arthroplasty; 7 were living with their original arthroplasty, and 15 died with a well-functioning implant in situ. Three were lost to follow-up.
CONCLUSIONS CONCLUSIONS
TEA is an effective and reliable procedure for the treatment of comminuted distal humeral fractures in the elderly patient. Our study reveals reliable implant long-term survival, with no patient requiring a late revision. For the majority of these patients, a well-performed TEA will give them a well-functioning elbow for life and will be the last elbow procedure required.

Identifiants

pubmed: 31445787
pii: S1058-2746(19)30419-7
doi: 10.1016/j.jse.2019.06.004
pii:
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2198-2204

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Journal of Shoulder and Elbow Surgery Board of Trustees. Published by Elsevier Inc. All rights reserved.

Auteurs

Niloofar Dehghan (N)

Department of Orthopaedic Surgery, University of Arizona College of Medicine, Phoenix, AZ, USA; The CORE Institute, Phoenix, AZ, USA.

Matthew Furey (M)

Division of Orthopaedic Surgery, Department of Surgery, University of Alberta, Edmonton, AB, Canada.

Laura Schemitsch (L)

Division of Orthopaedics, Department of Surgery, St. Michael's Hospital and University of Toronto, Toronto, ON, Canada.

Bill Ristevski (B)

Department of Surgery, McMaster University, Hamilton, ON, Canada.

Thomas Goetz (T)

Department of Orthopaedic Surgery, University of British Columbia, Vancouver, BC, Canada.

Emil H Schemitsch (EH)

Division of Orthopaedics, Department of Surgery, Western University, London, ON, Canada.

Michael McKee (M)

Department of Orthopaedic Surgery, University of Arizona College of Medicine, Phoenix, AZ, USA. Electronic address: michael.mckee@bannerhealth.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH